PRP for Elbow Bursitis
Explore how PRP injections can treat elbow bursitis. Learn about platelet-rich plasma therapy benefits, recovery, and results for elbow bursitis.
Elbow bursitis, olecranon bursitis, causes painful swelling at the bony tip of the elbow that can persist for months despite aspiration and conservative care. Corticosteroid injections reduce swelling quickly but carry a meaningful risk of bursal infection and skin atrophy in this superficial location. PRP (Platelet-Rich Plasma) is an emerging alternative for chronic or recurrent olecranon bursitis: direct RCT evidence for this specific condition is limited, but the biological rationale is sound and clinical evidence from adjacent bursitis conditions supports PRP's role as a durable, lower-risk option for patients who have failed or want to avoid repeat cortisone.
What Is Elbow Bursitis?
The olecranon bursa is a small fluid-filled sac that sits over the bony prominence at the back of the elbow, the olecranon. Its job is to cushion and reduce friction between the skin and the olecranon process. When the bursa becomes inflamed, it fills with fluid and produces the characteristic swelling: a soft, rounded lump at the elbow tip that can range from mildly tender to acutely painful.
Olecranon bursitis develops after prolonged pressure on the elbow (occupational or habitual leaning), direct trauma, inflammatory conditions (gout, rheumatoid arthritis), or without a clear cause. Septic (infected) bursitis requires antibiotic treatment and sometimes drainage, injection therapy is not appropriate until infection is excluded. Aseptic (non-infectious) olecranon bursitis is the target for conservative and injection-based treatments.
The olecranon bursa is uniquely superficial, it sits just beneath the skin, with minimal tissue protection. This anatomy makes cortisone injections effective but risky: the superficial location significantly increases the risk of infection, skin atrophy, and cutaneous sinus formation compared to deep bursal injections elsewhere. These risks are clinically meaningful and factor into treatment decisions for patients with chronic or recurrent disease.
Initial management includes aspiration, protective padding, activity modification, and NSAIDs. For persistent or recurrent bursitis, corticosteroid injection is the standard next step. For patients who have had cortisone with incomplete or short-lived benefit, or who have concerns about infection or repeat steroid exposure, PRP is a biologically rational alternative.
How PRP Works for Elbow Bursitis
PRP for olecranon bursitis is injected directly into the bursal space under ultrasound guidance. The concentrated platelet growth factors, PDGF, TGF-β, IGF-1, and VEGF, work to resolve the chronic inflammatory state within the bursal tissue and activate fibroblasts to produce collagen and support structural repair. The goal is to correct the underlying biology driving chronic bursal thickening and fluid accumulation, not simply suppress inflammation temporarily.
Ultrasound guidance allows the provider to visualize the bursa in real time, confirm fluid is present, and guide the needle into the bursal space accurately. Because the olecranon bursa is superficial, ultrasound also allows monitoring of the needle tip close to the skin surface, important for avoiding inadvertent subcutaneous or intradermal injection, which can cause soft-tissue damage at this thin-skinned location.
Unlike cortisone, PRP does not carry risks of skin atrophy, hypopigmentation, or infection from a steroid vehicle. For patients in whom these cortisone-related complications are a concern, particularly those who have had previous cortisone injections at this site or who have thin overlying skin, PRP avoids these risks while still delivering a biologically active treatment directly to the bursa.
What the Research Shows
Dedicated randomized controlled trial evidence for PRP in olecranon bursitis is currently absent from the medical literature. The condition itself has a limited clinical trial base, even for conventional treatments. A 2023 systematic review of non-surgical treatment for aseptic olecranon bursitis1, published in Reumatología Clínica, identified only 4 studies meeting inclusion criteria (2 RCTs, 2 observational) and found that clinical resolution can occur with conservative methods, while corticosteroid injection accelerates symptom resolution but carries a higher rate of complications including bursal infection and skin atrophy. PRP was not examined.
The most directly applicable bursitis PRP evidence comes from subacromial bursitis research. A 2024 double-blind randomized controlled trial of 100 patients with subacromial bursitis2, published in the Journal of Shoulder and Elbow Surgery, found that a single PRP injection produced significantly better pain, function, and sleep quality at 12 months compared to corticosteroid, with a treatment failure rate of 12% versus 30% in the cortisone group (p < 0.01). While the subacromial bursa is anatomically distinct from the olecranon bursa, both share the same bursal biology, chronic inflammation of a fluid-filled sac, and the PRP mechanism of action targets that shared biology.
A 2023 randomized trial of 180 patients with pes anserine bursitis comparing PRP, corticosteroid, and extracorporeal shockwave therapy3, published in Advances in Orthopedics, found that corticosteroid produced significantly better outcomes than PRP at both 1 week and 8 weeks. This study represents the only bursitis-specific head-to-head PRP versus cortisone comparison available in the literature, and its 8-week follow-up does not capture the longer-term outcomes where PRP's advantage over cortisone typically emerges in tendinopathy and joint research. The authors did not examine 6- or 12-month outcomes.
The honest summary: PRP has no dedicated RCT evidence for olecranon bursitis, and in the one available bursitis-specific PRP trial (pes anserine), cortisone outperformed PRP at 8 weeks. The clinical rationale for PRP in elbow bursitis rests on the subacromial bursitis data (superior 12-month outcomes), avoidance of cortisone's infection and skin complications in a superficial location, and use as a secondary option after cortisone has failed. Patients and providers should weigh this evidence gap honestly.
PRP vs. Cortisone for Elbow Bursitis
For most patients with acute or subacute olecranon bursitis after failed aspiration and conservative care, corticosteroid injection remains the standard first-line injection treatment. It reduces swelling and pain quickly, typically within 1–2 weeks, and most patients experience meaningful improvement. The important caveats are the elevated infection risk at this superficial location and the risk of skin atrophy with repeat injections.
PRP becomes a reasonable consideration in two scenarios: when cortisone has been tried without lasting benefit, or when a patient has had multiple cortisone injections and cumulative cortisone risks (skin changes, recurrent bursitis) make further steroid use undesirable. PRP works more slowly, improvement typically begins at 4–8 weeks, but does not carry cortisone's soft-tissue risks. For patients prioritizing safety over speed, or those with chronic recurrent bursitis, PRP is a biologically rational next step.
Who Is a Good Candidate?
PRP is most appropriate for patients with chronic or recurrent aseptic olecranon bursitis who have had aspiration and cortisone injection without lasting resolution, or who are concerned about further steroid exposure at this superficial site. Patients with significant bursal thickening and chronic wall changes on ultrasound, rather than simple acute fluid accumulation, are the most likely to benefit from a tissue-level treatment like PRP.
Septic (infected) bursitis must be excluded before any injection. The olecranon bursa is the most commonly infected bursa in the body, warmth, erythema, and systemic signs warrant aspiration and culture before proceeding with any injection therapy. Patients with gout or pseudogout causing bursitis should be treated appropriately for their underlying crystal arthropathy. Patients with large, fluctuant bursae that have not responded to multiple aspirations may be better served by surgical bursectomy.
What to Expect
Elbow bursitis PRP is performed as an outpatient procedure under ultrasound guidance. A blood draw is centrifuged to prepare the platelet-rich fraction, which is injected directly into the olecranon bursal space with real-time ultrasound confirming accurate placement. If significant fluid is present, aspiration may be performed immediately before PRP injection to decompress the bursa and maximize contact between the PRP and bursal wall. The procedure takes approximately 20–30 minutes.
Elbow rest and padding protection should continue for 2–4 weeks. Avoid direct pressure on the posterior elbow during recovery. Meaningful improvement in swelling and tenderness typically begins at 4–8 weeks. One injection is standard, with reassessment at 6–8 weeks. Recurrence is more likely if the underlying mechanical cause, habitual leaning on the elbow, repetitive pressure, is not addressed.
Explore related elbow conditions treated with PRP, including golfer's elbow (medial epicondylitis) and tennis elbow (lateral epicondylitis), or find a specialist in the OrthopedicPRP provider directory.
Sources
1. Kaur IP, Mughal MS, Aslam F, Schram J, Bansal P. Non-surgical treatment of aseptic olecranon bursitis: A systematic review. Reumatol Clin (Engl Ed). 2023;19(9):482-487. doi:10.1016/j.reumae.2023.05.004. PMID: 37945181.
2. Rossi LA, Brandariz R, Gorodischer T, et al. Subacromial injection of platelet-rich plasma provides greater improvement in pain and functional outcomes compared to corticosteroids at 1-year follow-up: a double-blinded randomized controlled trial. J Shoulder Elbow Surg. 2024;33(12):2563-2571. doi:10.1016/j.jse.2024.06.012. PMID: 39098382.
3. Gouda W, Abbas AS, Abdel-Aziz TM, et al. Comparing the Efficacy of Local Corticosteroid Injection, Platelet-Rich Plasma, and Extracorporeal Shockwave Therapy in the Treatment of Pes Anserine Bursitis: A Prospective, Randomized, Comparative Study. Adv Orthop. 2023;2023:5545520. doi:10.1155/2023/5545520. PMID: 37810418.
This content is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.
Elbow bursitis, known medically as olecranon bursitis, occurs when the small fluid-filled sac at the back of the elbow becomes inflamed and swollen. Whether caused by repetitive pressure, a direct blow, or inflammatory conditions like gout or rheumatoid arthritis, the result is a painful lump at the elbow tip that limits daily function. Platelet-rich plasma (PRP) therapy offers a regenerative option for chronic non-septic bursitis, targeting the underlying inflammatory tissue pathology rather than temporarily suppressing symptoms.
| Application | Injection Target | Evidence Level | Typical Protocol | Best Candidates |
|---|---|---|---|---|
| Olecranon Bursitis (Elbow Bursitis) | Olecranon bursal space under ultrasound guidance (often with aspiration first) | Limited (no dedicated olecranon bursitis PRP RCTs; adjacent bursitis evidence from subacromial RCT 2024 and pes anserine RCT 2023) | 1 injection under ultrasound guidance; reassess at 6–8 weeks | Chronic/recurrent aseptic bursitis; failed cortisone; cortisone infection risk concern; avoiding repeat steroid exposure |
Frequently Asked Questions
What Is Olecranon Bursitis?
The olecranon bursa is a small, fluid-filled sac located between the skin and the olecranon, the bony point at the back of the elbow. Under normal conditions, it contains only a thin layer of fluid that allows the skin to move freely over the bone. When irritated or inflamed, the bursa can fill dramatically with excess fluid, producing the characteristic swelling of olecranon bursitis.
There are two main categories: septic bursitis (caused by bacterial infection, most commonly Staphylococcus aureus) and non-septic bursitis (caused by mechanical stress, trauma, or systemic inflammatory conditions such as gout or rheumatoid arthritis). Septic bursitis requires antibiotics and possibly surgical drainage before any regenerative therapy is considered. Non-septic bursitis is the appropriate candidate for PRP. Bursal fluid aspiration and analysis are essential diagnostic steps to distinguish between these two types.
Find an Elbow Bursitis PRP Specialist Near You
Browse our directory of verified providers who offer PRP injections for olecranon bursitis and other elbow conditions.
Search ProvidersCauses, Risk Factors, and Diagnosis
Non-septic olecranon bursitis develops through several mechanisms. Repeated pressure or friction from leaning on hard surfaces, common in plumbers, students, and office workers, is among the most prevalent causes. Acute trauma, such as a fall directly onto the elbow, can trigger rapid inflammatory fluid accumulation. Systemic conditions like gout (urate crystal deposition) and rheumatoid arthritis (autoimmune synovial inflammation) create chronic bursal irritation. Risk factors include contact sports, diabetes, immunosuppressive medications, and chronic corticosteroid use.
Diagnosis is primarily clinical, based on the characteristic swelling, tenderness, and history. Ultrasound imaging can assess bursal size and internal characteristics, guide aspiration, and direct PRP injection with precision. Bursal fluid analysis (cell count, glucose, culture, crystal examination) definitively differentiates septic from non-septic bursitis and guides appropriate treatment selection.
How PRP Therapy Treats Elbow Bursitis
PRP therapy uses the patient's own concentrated growth factors to modulate the chronic inflammatory cycle driving non-septic bursitis. Blood is drawn (30–60 mL), centrifuged to isolate the platelet-rich layer, and injected into the affected bursa under ultrasound guidance. The resulting concentrate, typically 3–8 times baseline platelet concentration, delivers key bioactive proteins: IL-1Ra counteracts pro-inflammatory cytokines driving bursal fluid overproduction; TGF-β stimulates fibroblast proliferation and collagen synthesis to remodel the bursal lining; PDGF recruits reparative cells to the injection site; and VEGF supports controlled vascular remodeling.
Unlike corticosteroids, which suppress inflammation temporarily while progressively weakening connective tissue with repeated use, PRP aims to correct the underlying tissue pathology. Most patients receive 1–3 injections spaced 4–6 weeks apart. A brief rest of 24–48 hours is advised post-injection. NSAIDs should be avoided for 1–2 weeks following injection to preserve the healing response; acetaminophen may be used for pain management instead.
Recovery, Outcomes, and Evidence
Most patients experience a temporary increase in pain and swelling for 2–7 days after PRP injection, reflecting the acute inflammatory phase of tissue repair. Clinical improvement typically begins within 4–6 weeks and continues over 3–6 months. Outcomes for chronic non-septic olecranon bursitis include significant pain reduction, decreased bursal swelling, and return to normal daily activities.
A 2020 systematic review in the Journal of Orthopaedic Research found PRP superior to corticosteroid injections for chronic periarticular soft tissue disorders, including bursitis, with sustained pain reduction at 12 months (PMID: 31696561). Research on greater trochanteric bursitis, a closely analogous bursal condition, documented significant improvement following ultrasound-guided PRP injection, supporting PRP's applicability across bursal disorders (Muscles Ligaments Tendons J, 2022). Evidence specifically for olecranon bursitis continues to grow through case series and prospective studies.
| Treatment Option | Mechanism | Duration of Relief | Key Considerations |
|---|---|---|---|
| PRP Injection | Regenerative growth factors | 6–12+ months | Addresses tissue pathology; low side-effect profile |
| Corticosteroid Injection | Anti-inflammatory suppression | Weeks to months | Tissue atrophy risk with repeated injections |
| Aspiration Alone | Fluid volume reduction | Often temporary | High recurrence without treating inflammation |
| NSAIDs (Oral) | Systemic anti-inflammatory | While medicating | GI and renal side effects; no structural repair |
| Surgical Bursectomy | Bursa removal | Permanent if successful | Invasive; wound and nerve complication risks |
Frequently Asked Questions
Ready to Explore PRP for Your Elbow Bursitis?
Our specialists provide ultrasound-guided PRP treatment tailored to your specific condition and recovery goals.
Schedule a ConsultationOther Conditions
PRP for Achilles Tendinitis
Explore how PRP injections can treat achilles tendinitis. Learn about platelet-rich plasma therapy benefits, recovery, and results for achilles tendinitis.
PRP for ACL Injuries
Explore how PRP injections can treat acl injuries. Learn about platelet-rich plasma therapy benefits, recovery, and results for acl injuries.
PRP for Ankle Sprains
Explore how PRP injections can treat ankle sprains. Learn about platelet-rich plasma therapy benefits, recovery, and results for ankle sprains.
PRP for Carpal Tunnel Syndrome
Explore how PRP injections can treat carpal tunnel syndrome. Learn about platelet-rich plasma therapy benefits, recovery, and results for carpal tunnel syndr...
PRP for Chronic Low Back Pain
Explore how PRP injections can treat chronic low back pain. Learn about platelet-rich plasma therapy benefits, recovery, and results for chronic low back pain.
PRP for De Quervain's Tenosynovitis
Explore how PRP injections can treat de quervain's tenosynovitis. Learn about platelet-rich plasma therapy benefits, recovery, and results for de quervain's ...
PRP for Disc Degeneration
Explore how PRP injections can treat disc degeneration. Learn about platelet-rich plasma therapy benefits, recovery, and results for disc degeneration.
PRP for Facet Joint Syndrome
Explore how PRP injections can treat facet joint syndrome. Learn about platelet-rich plasma therapy benefits, recovery, and results for facet joint syndrome.
PRP for Frozen Shoulder
Explore how PRP injections can treat frozen shoulder. Learn about platelet-rich plasma therapy benefits, recovery, and results for frozen shoulder.
PRP for Golfer's Elbow
Explore how PRP injections can treat golfer's elbow. Learn about platelet-rich plasma therapy benefits, recovery, and results for golfer's elbow.